Vaginal gel or shot: which better prevents preterm birth?

NCT ID NCT02913495

Completed Prevention Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two forms of progesterone—vaginal gel and a shot—to see which works better at preventing another preterm birth in women who had one before. About 210 pregnant women with a prior preterm birth took part. The goal was to find out if the vaginal option is more effective than the standard shot.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: progesterone (vaginal or intramuscular)
What this could lead to: If successful, this could show that vaginal progesterone is better at preventing recurrent preterm birth than the standard shot, offering a simpler option.
What could go wrong: This trial is completed but results are not yet widely confirmed. It only included women with a prior preterm birth, so findings may not apply to all pregnant women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREMATURE BIRTH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREMATURE BIRTH

Contacts and locations

Show contact details

Locations

Baystate Medical Center

Springfield, Massachusetts, 01199, United States
George Washington University

Washington D.C., District of Columbia, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.